Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327
- The ASX-lister announced it had registered R327 with the Australian and New Zealand Clinical Trial Registry for a phase I/II topical burns study
- The study is set to test 30 patients over two weeks in a bid to test the efficacy of the drug
- In a broader context, Recce said the application represents one of the final administration stages required before the trial can commence
- Recce Pharmaceuticals is up 6.63 per cent following the announcement, trading at $1.26
Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327.
The company today announced the drug had been registered with the Australian and New Zealand Clinical Trial Registry (ANZCTR) for a phase I/II topical burns study in humans.
In a broader context, Recce said the registration represents one of the final administration stages required before the trial can commence.
The ANZCTR includes trials from the full spectrum of therapeutic areas of pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment and rehabilitation strategies and complementary therapies.
The trial has been registered under ‘Proof of Concept Study of RECCE 327 Topical
Antibiotic Therapy for Infected Burn Wounds in Adults’ and will involve 30 patients to test the efficacy of RECCE 327.
Over the course of 14 days, 10 patients are set to receive R327 daily while the remaining 20 receive treatment three times per week.
Recce Pharmaceuticals is up 6.63 per cent following the announcement, trading at $1.26 at 3:42 pm AEST.
